Silence Therapeutics (SLN) Cash & Current Investments (2018 - 2026)

Silence Therapeutics has disclosed Cash & Current Investments across 9 years of filings, most recently posting $70.1 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $70.1 million, down 48.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.1 million (down 48.67% YoY), and the FY2025 annual result was $85.1 million, down 54.26% from the prior year.
• Cash & Current Investments came in at $70.1 million for Q1 2026 at Silence Therapeutics, down from $85.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $186.1 million in Q4 2024 to a low of $49.2 million in Q4 2022.
• The 5-year median for Cash & Current Investments is $93.7 million (2025), against an average of $101.4 million.
• Across the five-year window, Cash & Current Investments jumped 173.67% in 2024 and sank 54.26% in 2025, its largest moves.
• Silence Therapeutics' Cash & Current Investments stood at $49.2 million in 2022, then surged by 38.06% to $68.0 million in 2023, then surged by 173.67% to $186.1 million in 2024, then tumbled by 54.26% to $85.1 million in 2025, then slipped by 17.67% to $70.1 million in 2026.
• The last three Cash & Current Investments figures came in at $70.1 million (Q1 2026), $85.1 million (Q4 2025), and $102.2 million (Q3 2025), per Business Quant data.